United States

Versartis closes $25M Series C financing

Wednesday, January 16, 2013 10:24 AM

Versartis, an emerging biotechnology company focused on endocrine disorders, has completed a $25 million Series C financing lead by new investor Aisling Capital. The primary use of the proceeds will be to fund clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in pediatric patients. VRS-317 is a proprietary once monthly form of recombinant human growth hormone (rhGH).

More... »

Velocity Pharmaceutical announces clinical development agreement

Wednesday, January 16, 2013 09:55 AM

Velocity Pharmaceutical Development, is a pharmaceutical development organization, has signed a licensing agreement to pursue a drug development program utilizing EuMederis Pharmaceuticals' EuPort technology for optimizing the pharmaceutical properties of peptide drugs.

More... »

ActiGraph launches ActiLife Mobile app

Tuesday, January 15, 2013 10:32 AM

Pensacola, Fla.-based ActiGraph, a provider of objective patient monitoring solutions for the global research community, has released a new mobile app for researchers.

More... »

Partners HealthCare, Illumina announce founding members of GeneInsight Network

Monday, January 14, 2013 02:49 PM

Partners HealthCare, a Boston-based integrated health system, and Illumina, a developer, manufacturer and marketer of life science tools and integrated systems, announced the GeneInsight-Illumina Founding Network Members, including the ARUP Laboratories, Mount Sinai Genetic Testing Laboratory, New York Genome Center (NYGC), Partners HealthCare and Illumina.

More... »

GVK Biosciences, Onconova partner to advance new cancer drugs

Monday, January 14, 2013 01:23 PM

GVK Biosciences, a contract research and development organization, has entered into a novel joint partnership with Onconova Therapeutics, a Newtown, Penn.-based biopharmaceutical company focused on novel small molecules for oncology, to develop new drugs for cancer.

More... »

Catalent invests $20M to expand inhalation capabilities

Monday, January 14, 2013 12:04 PM

Catalent Pharma Solutions, Somerset, N.J.-based developer of solutions and drug delivery technology, is investing $20 million to expand its inhalation drug development, delivery and supply capabilities by enhancing its Inhalation Center of Excellence in Research Triangle Park in North Carolina. The investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities as well as other enhancements to the facility.

More... »

ArisGlobal launches enhanced global trial disclosure and compliance solution

Monday, January 14, 2013 10:39 AM

ArisGlobal, a provider of integrated software solutions for pharmacovigilance and safety, regulatory affairs, clinical research and medical information, has launched agDisclosure 3.1, a comprehensive system that enables sponsors to plan, prepare and manage submissions to multiple registries with ease. 

More... »

Telik receives Orphan status for Telintra for myelodysplastic syndrome

Monday, January 14, 2013 09:42 AM

Telik, a clinical stage drug development company focused on developing small molecule drugs to treat cancer, was notified today that its product candidate, ezatiostat HCL (Telintra), has been granted Orphan Drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS). 

More... »

MorphoSys completes sale of AbD Serotec to Bio-Rad

Friday, January 11, 2013 01:55 PM

MorphoSys, a biotechnology company focusing on fully human antibodies, has completed the sale of its research and diagnostic antibody segment AbD Serotec to Waltham, Mass.-based Bio-Rad Laboratories.

More... »

Cyberonics names KenKnight as vice president of emerging therapies

Friday, January 11, 2013 12:33 PM

Cyberonics, a medical technology company with core expertise in neuromodulation, has appointed Bruce H. KenKnight, Ph.D., as vice president of Emerging Therapies.

More... »